Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Current Opinion in Urology

Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

KOKarima OuallaInstitut Jules BordetMAMehdi AlemSidi Mohamed Ben Abdellah UniversityJTJeremy Yuen‐Chun TeohChinese University of Hong Kong

Discussion

Loading...

Member takes

Implication

Review reveals improved outcomes with immune checkpoint inhibitors and novel therapies in NMIBC patients, suggesting new treatment options.

Key Points

  • Systemic immunotherapy shows promise in treating BCG-refractory nonmuscle-invasive bladder cancer.
  • Immune checkpoint inhibitors like pembrolizumab have received regulatory approval and demonstrate therapeutic success.
  • Combination regimens with immunotherapy and other treatments are being explored to enhance efficacy.
  • New molecular targets and tailored strategies reflect the ongoing advances in managing this challenging patient population.

Cite This Study

Oualla et al. (2025) studied this question.

synapsesocial.com/papers/68d44f8c31b076d99fa57494https://doi.org/10.1097/mou.0000000000001334
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment2014 · 565 citations
  2. 2The application of Toll like receptors for cancer therapy2010 · 144 citations
  3. 3Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer2000 · 148 citations
  4. 4Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences2010 · 103 citations